WO2013044105A1 - Nanotubes et compositions de ceux-ci - Google Patents

Nanotubes et compositions de ceux-ci Download PDF

Info

Publication number
WO2013044105A1
WO2013044105A1 PCT/US2012/056674 US2012056674W WO2013044105A1 WO 2013044105 A1 WO2013044105 A1 WO 2013044105A1 US 2012056674 W US2012056674 W US 2012056674W WO 2013044105 A1 WO2013044105 A1 WO 2013044105A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
absent
implant
formulation
cells
Prior art date
Application number
PCT/US2012/056674
Other languages
English (en)
Inventor
Thomas J. Webster
Original Assignee
Brown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brown University filed Critical Brown University
Publication of WO2013044105A1 publication Critical patent/WO2013044105A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
    • A61F2/30771—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth applied in original prostheses, e.g. holes or grooves
    • A61F2002/3084—Nanostructures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Definitions

  • the present invention relates to the field of implants, and more particularly to the modification of the surface of implants using polypeptide-functionalized nanotubes.
  • the present invention further relates to the modification of the surface of an implant device using certain polypeptide-functionalized nanotubes to selectively promote adhesion of certain cells to the surface of the implant device.
  • the surface of an implant modified to include polypeptide-functionalized nanotubes promotes the adhesion of osteoblasts to the implant.
  • the present invention also relates to methods, compositions and composites including nanotubes for tissue repair and regeneration.
  • compositions or composites including nanotubes, nanoparticles and matrix materials for tissue repair and regeneration which can placed at a site within the body and on or into which growth of tissue can be promoted.
  • Embodiments of the present invention are directed to methods of altering the surface of a substrate to improve cell adhesion, proliferation and/or differentiation on the surface of the substrate.
  • Substrates within the scope of the present invention include implant surfaces where cell adhesion is desired and/or cellular growth and/or cellular differentiation on the substrate itself or at the location of the implant within the body. Examples of such implants are those associated with orthopedic applications.
  • the surface of the implant is modified to include a nanostructured outer surface. An implant with such a surface according to the present invention provides greater cell adhesion as compared to an implant without the nanostructured outer surface.
  • Certain embodiments of the present invention are directed to coatings on the surface of implants that selectively promote adhesion of certain cell types to the surface of the implant.
  • the coatings provide a desirable surface chemistry or condition which promotes selective cell adhesion, proliferation and/or differentiation.
  • the coating is biomimetic.
  • Coatings according to certain embodiments of the present invention include nanometer scale molecular architectures, such as nanotubes, that include moieties or sidechains that selectively promote adhesion of certain cell types to the surface of the implant. Further embodiments allow for the selective adhesion of certain cell types compared to other certain cell types.
  • the nanometer scale molecular architectures can be used alone or in combination with components suitable for creating a coating on the surface of a substrate and for proliferating and/or differentiating cells.
  • the coatings that include the nanometer scale molecular architectures promote the adhesion of selected cells and growth of tissue on the surface of the implant.
  • the coatings that include the nanometer scale molecular architectures are osteogenic insofar as they promote the adhesion of osteoblasts and the growth of the osteoblasts into bone tissue.
  • compositions can be in the form of injectable liquids, moldable putties or hardened structures.
  • the hardened structures may be rigid, semirigid, or flexible.
  • the hardened structures may be porous or nonporous.
  • the injectable liquids and moldable putties may harden when placed within the environment of the body.
  • composites within the present disclosure can be injected as a liquid and solidify in situ simply through exposure to body temperatures. It is to be understood that the injectable liquids, moldable putties or hardened structures can be referred to as implants.
  • the composition includes the nanometer scale molecular architectures, a compound providing mechanical strength and a matrix material.
  • the composition can be placed at a site within the body where structural support is desired.
  • the composition can be placed within the body where tissue growth or regeneration is desired.
  • the composition can be placed within the body where a combination of structural support and tissue growth or regeneration is desired.
  • the composition can be permanent or biodegradable or bioresorbable.
  • the composition can also be fashioned into various implant shapes to occupy a site where tissue has been removed such as a bone chip or fracture.
  • the composition can also be fashioned into devices useful in rebuilding damaged tissue sites such as plates, rods, screws, cages, scaffolds, films, and coatings. The size, shape and manufacture of such devices including the compositions described herein and their use is well known to those of skill in the art and will be readily apparent based on the present disclosure.
  • the composition or composite selectively promotes the adhesion of certain cell types to the surface of the composition or composite.
  • the composition provides a desirable surface chemistry or nanometer scale surface geometry or condition which promotes selective cell adhesion, proliferation and/or differentiation.
  • the composition is biomimetic.
  • the composition of the present disclosure includes nanometer scale molecular architectures, such as nanotubes, that in some embodiments include moieties or sidechains that selectively promote adhesion of certain cell types to the surface of the implant. Further embodiments include nanoparticles in addition to the nanotubes to provide a nanometer scale surface geometry intended to promote cell adhesion, proliferation and/or differentiation. Further embodiments allow for the selective adhesion of certain cell types compared to other certain cell types.
  • Embodiments of the present invention are also directed to modules, including functionalized modules that self-assemble into more complex structures on a nanometer scale, such as a nanotube.
  • the functionalized modules include one or more moieties that promote the adhesion of cells when present in a coating on the surface of a substrate, such as the surface of an implant.
  • the nanometer scale structure can include several different moieties, i.e. two or more moieties or a plurality of moieties, that selectively promote adhesion of certain cell types.
  • the certain cell types include those useful in promoting the expansion and growth of cells into tissue.
  • the certain cell types include osteoblasts, fibroblasts, endothelial cells, keratinocytes, cardiac myocytes, chondrocytes, synoviocytes, mesenchymal stem cells, neural stem cells, islet cells, hepatocytes, smooth muscle cells, urothelial cells, neurons, Schwann cells and the like.
  • Embodiments of the present invention are also directed to methods of selectively tailoring cell adhesion to the surface of an implant.
  • a moiety is selected that will promote the adhesion of a particular cell type.
  • the adhesion can be in vitro, i.e. before the implant is implanted, or in vivo, i.e. after the implant is implanted.
  • the moiety is included into a module which is then assembled into a substructure.
  • the substructure is then assembled into a nanometer scale molecular architecture, such as a nanotube.
  • the assembly is a self- assembly insofar as the modules are placed into an aqueous medium where they self assemble into a substructure such as a ring structure, such as a rosette, and the ring structures then self-assemble by stacking one on top of another to form a tubular structure, commonly referred to as a nanotube.
  • a substructure such as a ring structure, such as a rosette
  • the ring structures then self-assemble by stacking one on top of another to form a tubular structure, commonly referred to as a nanotube.
  • Such modules, substructures and nanometer scale molecular structures and their self-assembly is described in US 6,696,565, Fenniri et al, J. Am. Chem. Soc. 2001, 123, 3854-3855, Moralez et al, J. Am. Chem. Soc, 2005, 127, 8307-8309, and Fine et al, International Journal of Nanomedicine 2009:4 91
  • one example of a nanometer scale molecular architecture is a nanotube having nanometer scale dimensions.
  • the nanotubes range in lengths between about 1 nm and about 999 microns, 10 nm and about 10,000 nm, 1 nm to about 500 nm, about 10 nm to about 300 nm, or about 20 nm to about 100 nm.
  • the nanotubes range in diameters between about 1 angstrom and about 100 nm or about 3 nm to about 20 nm.
  • the openings through the nanotubes range in diameters between about 1 angstrom and about 100 nm or about 3nm to about 20 nm.
  • the nanotubes are monodispersed in diameter for a given functionality attached to a nanotube.
  • the diameter can vary between about 1 nm to about 30 nm, or from about 3 nm to about 15 nm.
  • the opening through the nanotube can range in diameter between about 1 nm to about 30 nm, or from about 3 nm to about 15 nm.
  • the opening through the nanotube has a diameter of about 1 nm.
  • the nanometer scale molecular architecture can include two or more moieties each selective for a different cell type.
  • the nanometer scale molecular architecture can then be coated on the surface of an implant whether partly or entirely or fashioned into an implant, whether in liquid, putty or solid form.
  • the implant can then be implanted at the desired site within a patient, human or animal, in need of such an implant. Desired cells adhere to the surface of the implant and the desired tissue will grow.
  • the desired cells can be applied and adhered to the surface of the implant before implantation.
  • Such embodiments are useful to promote the growth of tissue on the implant or at the site of implantation.
  • adhesion and adherence are used interchangeably and refer to the ability of the cells to remain on the surface of a substrate when subjected to rinsing with saline as known in the art.
  • Embodiments of the present invention are still further directed to compositions including nanometer scale molecular architectures having functional moieties attached thereto.
  • the functional moieties can have therapeutic or diagnostic applications.
  • the nanometer scale molecular architectures can be used as vehicles for the delivery of functional moieties to a particular site for therapeutic or diagnostic application.
  • the functionalized nanometer scale molecular architectures are mixed with a pharmaceutically acceptable excipient or delivery vehicle and then delivered to the desired location.
  • the nanometer scale molecular architectures of the present invention such as nanotubes, can mimic the mechanical properties of cartilage when mixed with ceramics and can self-assemble into a material that can mimic the properties of bone.
  • the nanometer scale molecular architectures are nonfunctionalized or functionalized with moieties useful in orthopedic, cartilage, vascular and wound healing applications, in addition to therapeutic and diagnostic applications.
  • modules as described herein which are nonfunctionalized or functionalized for a particular purpose are delivered to a desired site within the body, such as by injection or physical placement as with a putty, where conditions within the body such as temperature and aqueous environment cause the modules to self-assemble into nanotubular structures, preferably solidify, and promote the growth of tissue in the particular environment.
  • the modules are a component of a composition including a strengthening compound for providing mechanical strength and a matrix material. The composition is placed within the body where conditions within the body such as temperature and aqueous environment causes the modules to self- assemble into nanotubular structures and the composition to cure or polymerize or otherwise solidify into a hardened implant.
  • the modules are already self-assembled into nanotube structures before delivery to a site within the body.
  • the modules or self-assembled nanotube structures are injected into a fractured bone, cartilage, vascular tissue, heart tissue, nervous system tissue, etc. where the self-assembled nanotubes promote the growth of useful tissue.
  • the self-assembled nanotubes can be applied to the surface of skin to serve as a wound healing device.
  • methods and compositions are provided for promoting osteoblast differentiation and proliferation, for example at the site of a bone injury or defect or surgical site, including providing an implant with a composition including nanotubes formed from modules according to formula I and/or formula II described herein, nanoparticles, such as nanoparticles of a calcium phosphate and a matrix material, and placing the implant within the body at a site where osteoblast differentiation and proliferation is desired.
  • the nanometer scale surface geometry of the composition resulting from the nanotubes and the nanoparticles within the matrix promotes the differentiation and proliferation of osteoblasts and the growth of bone tissue.
  • methods and compositions for promoting osteoblast differentiation and proliferation while inhibiting fibroblast proliferation including providing an implant with a composition including nanotubes formed from modules according to formula I and/or formula II described herein, nanoparticles, such as nanoparticles of a calcium phosphate and a matrix material, and placing the implant within the body at a site where osteoblast differentiation and proliferation is desired.
  • the nanometer scale surface geometry of the composition resulting from the nanotubes and the nanoparticles within the matrix promotes the differentiation and proliferation of osteoblasts and inhibits fibroblast proliferation.
  • compositions for treating bone defects providing an implant with a composition including nanotubes formed from modules according to formula I and/or formula II described herein, nanoparticles, such as nanoparticles of a calcium phosphate and a matrix material, and placing the implant within the body at a site of a bone defect, such as a fracture, or where bone is missing.
  • a bone defect such as a fracture, or where bone is missing.
  • the hardened composition with nanometer scale surface geometries resulting from the nanotubes and the nanoparticles within the matrix provides sufficient mechanical support and promotes the differentiation and proliferation of osteoblasts and the deposition of calcium to treat the bone defect.
  • the hardened composition with nanometer scale surface geometries resulting from the nanotubes and the nanoparticles within the matrix provides sufficient mechanical support and promotes the differentiation of stem cells into osteoblasts and further promotes proliferation of the osteoblasts and the deposition of calcium to treat the bone defect.
  • the composition can be in the form of an injectable liquid or shapeable putty and can include stem cells or osteoblasts.
  • stem cells or osteoblasts can be applied to a tissue defect site before application of the composition to the tissue defect site or simultaneously along with the composition to the tissue defect site.
  • Figure 1A-1D Depiction of the self-assembly process of various modules into rosette nanotubes.
  • FIG. 1E-1G Twin base RNTs.
  • E TB-KRSR;
  • F TBL;
  • G The self-assembly process of twin CAG bases into a rosette nanotube.
  • FIG. 1 A synthetic scheme of (A) Wang resin protected KRSR peptide coupling onto the twin CAG bases (TB-KRSR) and (B) twin CAG bases with a 1 ,4-diaminobutane linker (TBL).
  • FIG. 3 TEM images of the various RNTs: (A) and (B) 0.1 mg/mL and 0.01 mg/mL TB-KRSR RNTs; (C) and (D) 0.1 mg/mL TBL RNTs (HCl and TFA, respectively); (E) 0.1 mg/mL MB-K RNTs; (F) 0.1 mg/mL 5% MB-RGD-K RNTs; and (G) 0.1 mg/mL KRSR peptide only without nanotubes. Arrows show the nanotubes.
  • FIG. 1 Fluorescent microscopy images of osteoblast adhesion on RNT coated on titanium at low (original magnification 50 x , DAPI stained nuclei) and high magnifications (400 x , rhodamine-phalloidin stained F-actin filaments).
  • FIG. 8 Fluorescent microscopy images of fibroblast spreading.
  • A MB-K RNTs coated on titanium;
  • B TBL RNTs (HCl) coated on titanium;
  • C 1% MB-RGD-K RNTs coated on titanium;
  • D TB-KRSR RNTs coated on titanium;
  • E KRSR coated on titanium; and
  • F uncoated titanium.
  • F-actin filaments were stained by rhodamine- phalloidin.
  • FIG. 10 Fluorescent microscopy images of endothelial cell spreading on various coatings after 4 h.
  • A MB-K RNTs coated on titanium;
  • B TBL RNTs (HCl) coated on titanium;
  • C 1% MB-RGD-K RNTs coated on titanium;
  • D TB-KRSR RNTs coated on titanium;
  • E KRSR coated on titanium; and
  • F uncoated titanium.
  • F-actin filaments were stained by rhodamine-phalloidin (green color) and cell nuclei were stained by DAPI (blue color).
  • FIG. 11 Graph of temperature curves of TBL /HA/pHEMA composites after (a) sonication and (b) microwave. [031] Figure 12. Graph of solidification time of varying (a) water ratios and (b) AIBN initiator concentrations.
  • Figure 13 AFM image of nanotubes framed from twin base linkers.
  • Figure 18 Graph of degradation of composites of nanotubes formed from twin base linkers, hydroxyapatite and poly hydroxyethylmethacrylate after 7 days.
  • Figure 19 Graph of degradation of composites of nanotubes formed from twin base linkers, hydroxyapatite and poly hydroxyethylmethacrylate after 1 month. *p ⁇ 0.05 compared with the 2%HA no TBL group.
  • FIG. 25 Graph of chondrocyte cell adhesion on TBL/pHEMA composites for 4 h.
  • N 3. P ⁇ 0.05, compared to pHEMA no TBL samples. (*) p ⁇ 0.05 compared to pHEMA without TBL composites.
  • Figure 27 Graph of chondrocyte total protein synthesis after 3 and 5 day culturing.
  • FIG. 30 Graph of fibroblast cell density on pHEMA composites for 1, 3, and 5 d culturing.
  • Cell seeding density is 3500 cells/cm 2 .
  • Cell density was indicated as the average number of cells/cm 2 on sample surface.
  • FIG. 31 Graph of ultimate tensile strength of TBL/HA/pHEMA composites.
  • the Instron 5882 mechanical testing system was used to determine the tensile properties of samples at a speed of 5 mm/min under dry conditions.
  • Figure 32 Masson-Goldner stain of new bone growth demonstrating greater bone tissue ingrowth area after 4 weeks.
  • Figure 33 Masson-Goldner stain of new bone growth demonstrating greater bone tissue ingrowth distance after 4 weeks.
  • FIG. 34 Histology of TBL with 20 wt. % HA and controls after 4 weeks of implantation.
  • Figure 35 Masson-Goldner stain of new bone growth demonstrating greater bone tissue ingrowth area after 8 weeks.
  • Figure 36 Masson-Goldner stain of new bone growth demonstrating greater bone tissue ingrowth distance after 8 weeks.
  • Figure 37 Histology of TBL with 20 wt. % HA and controls after 8 weeks of implantation.
  • FIG. 38 Histology of TBL with 20 wt. % HA and controls after 12 weeks of implantation.
  • Embodiments of the present invention are based on the discovery that implant surfaces may be tailored to enhance or promote the adhesion of selective cell types using nanometer scale architectures or structures that can preferably be biomimetic, namely having structural similarity to structures found in nature.
  • the nanometer scale structures are formed from modules that preferably self-assemble into substructures, which themselves self-assemble into the nanometer scale architectures or structures, when placed in an aqueous environment such as body fluids.
  • Embodiments of the present invention are further directed to compositions including the nanometer scale structures, such as self assembled nanotubes, a strengthening compound providing mechanical strength, an optional nanoparticle and a matrix material.
  • compositions can be flowable or moldable such that they can be placed in or occupy or form-fit into a desired site, space or location with the body, such as by syringe, trocar or by hand, and then cured into a hardened structure to provide a nanometer scale surface geometry, to mechanical strength and/or to promote tissue growth or regeneration.
  • the viscosity of the composition can be altered to between a flowable liquid and a less flowable putty. As a composition becomes more viscous, it may be more putty-like. Similarly, as a composition becomes less viscous, it may be described as a flowable or liquid material. However, as a person of ordinary skill in the art would be aware, the states of being "flowable” or "putty-like" exist along a continuum.
  • Modules according to the present invention include compounds of Formula I below:
  • X is CH or nitrogen; Y is absent or an amino acid or polypeptide; R 2 is absent or a linker and Ri is aliphatic.
  • Y is an amino acid or polypeptide having an amino group covalently bound to an a-carbon of the amino acid and the amino group is covalently bound to a linker group R 2 for example (CH 2 ) n ; n is an integer of, 1 , 2, 3, or 4, and Ri is aliphatic, such as alkyl, straight or branched chain, saturated or unsaturated; and salts thereof.
  • Ri is Ci to C 10 alkyl, Ci to C 5 alkyl, Ci to C 3 alkyl, or methyl.
  • Compounds within the scope of the invention include those where the Y group can be connected to the linker group either by the amino group or the carboxyl group of the amino acid or polypeptide.
  • An exemplary linker group is shown in the formula below.
  • Alternative linker groups R 2 can join the Y group to the carbon of the (CH 2 ) n group or the N atom either by the amino group or the carboxyl group of the amino acid or polypeptide.
  • Linker moieties within the scope of the invention include NH 3 + and the following:
  • Modules according to the invention also include compounds of Formula II below:
  • X is CH or nitrogen; Y is absent or an amino acid or polypeptide; R 2 is absent or a linker and Ri is aliphatic.
  • Y is an amino acid or polypeptide having an amino group covalently bound to an a-carbon of the amino acid and the amino group is covalently bound to a linker group R 2 , such as (CH 2 )3CO; and Ri is aliphatic, such alkyl, straight or branched chain, saturated or unsaturated; and salts thereof.
  • Ri is Ci to C 10 alkyl, Ci to C 5 alkyl, Ci to C 3 alkyl, or methyl.
  • An exemplary linker group is shown in the formula below. Compounds within the scope of the invention include those where the Y group can be connected to the linker group either by the amino group or the carboxyl group of the amino acid or polypeptide.
  • Alternative linker groups R 2 connecting the NH + group and the Y group include
  • the structure of Formula II may be referred to as a twin base with a linker (TBL) or twin base linkers insofar as two similar double ring structures are present as shown in Formula II and are linked and further may include an amino acid or polypeptide.
  • TBL twin base with a linker
  • twin base linkers insofar as two similar double ring structures are present as shown in Formula II and are linked and further may include an amino acid or polypeptide.
  • the two double ring structures need not be identical insofar as they may have different X and Ri groups.
  • Amino acids according to the present invention include the commonly known amino acids such as glycine (Gly, G), alanine (Ala, A), valine (Val, V), leucine (Leu, L), isoleucine (He, I), proline (Pro, P), hydroxyproline, phenylalanine (Phe, F), tyrosine (Tyr, Y), tryptophan (Trp, W) cysteine (Cys, C), methionine (Met, M) serine (Ser, S), o- phosphoserine, threonine (Thr, T), lysine (Lys, K), arginine (Arg, R), histidine (His, H), aspartate (Asp, D), glutamate (Glu, E), ⁇ -carboxyglutamate, asparagine (Asn, N), glutamine (Gin, Q) and the like.
  • amino acids such as glycine (Gly, G),
  • Amino acids also include stereoisomers thereof and compounds structurally similar to the amino acids or modifications or derivatives thereof.
  • Exemplary amino acids within the scope of the present invention include those that improve adhesion of cells to the surface of a substrate. Accordingly, these amino acids are referred to as cell adhesion promoting amino acids.
  • Specific cell adhesion promoting amino acids include lysine, arginine, serine, glycine, aspartate and the like.
  • Polypeptides according to the present invention include two or more amino acids covalently linked together. According to one aspect, the two or more amino acids are covalently linked together at least in part by one or more peptide bonds. Exemplary polypeptides within the scope of the present invention include those that improve adhesion of cells to the surface of a substrate. Accordingly, these polypeptides are referred to as cell adhesion promoting polypeptides.
  • Specific cell adhesion promoting polypeptides include lysine-arginine-serine-argine (K SR), arginine-glycine-aspartate (RGD), isoleucine-lysine -valine-alanine -valine (IKVAV), tyrosine-isoleucine-glycine- serine-arginine (YIGSR) and the like. It is to be understood that other polypeptides having cell adhesion promoting characteristics are within the scope of the present invention which will be recognized by those of skill in the art having the benefit of this disclosure.
  • adhesion between osteoblasts and the KRSR polypeptide is believed to operate via heparin sulphate proteoglycan mediated mechanisms. See Dee et al, J. Biomed. Mater. Res., 1998;40:371-377 incorporated herein by reference.
  • modules (compounds) according to Formula I and Formula II self-assemble into substructures also called supermacrocycles which themselves will self-assemble into nanometer scale architectures or structures such as discrete nanotubular assemblies in water or aqueous solutions.
  • supermacrocycles are defined herein as being a number of organic molecules covalently or noncovalently bound together so as to form a ring structure.
  • compounds of Formula I will self-assemble into a 6-mer ring structure, sometimes referred to as a rosette.
  • the process of forming nanotubes with the modules of the present invention is hierarchical.
  • the modules of the present invention first self-assemble into supermacrocycles, and then the supermacrocycles self-assembly into nanotubes.
  • Such self-assembly is described in US 6,696,565.
  • the compounds of Formula II which include twin base linkers, the compounds will also assemble into a 6-mer ring structure.
  • a single supermacrocycle formed will include two base layers owing to the presence of the two bases in each of the compound of Formula II.
  • the compounds of Formula I and Formula II include low molecular weight synthetic DNA base analogues referred to by the nomenclature CAG. See Fenniri et al, J. Am. Chem. Soc. 2001, 123, 3854-3855.
  • the CAG moiety referred to as a single CAG motif, possess the Watson-Crick donor-donor- acceptor of guanine and the acceptor-acceptor-donor of cytosine and undergoes a self- assembly process, fueled by an array of hydrogen bonds, to produce a six-membered supermacrocycle or rosette. Stacking of these rosettes produced a nanotube of very high aspect ratio.
  • twin G A C motif denoted as (CAG) 2 .
  • the twin CAG motif (CAG) 2 also possesses the Watson-Crick donor-donor-acceptor of guanine and the acceptor-acceptor- donor of cytosine and undergoes a self assembly process, fueled by an array of hydrogen bonds, to produce a six-membered supermacrocycle or ring structure (rosette) of twin configuration. Stacking of these twin rosettes produces a nanotube of very high aspect ratio and higher stability.
  • a supermacrocycle ring substructure having particular amino acid or polypeptide side chains formed from the compounds of Formula I can be stacked with a supermacrocycle ring substructure having particular amino acid or polypeptide side chains formed from compounds of Formula II.
  • the rosette substructures formed from the compounds of Formula I and Formula II can be stacked in any desired sequence to form nanotubular structures of the present invention.
  • the nanotubular structures possess the amino acids or polypeptides that promote adhesion of selected cells to the nanotubular structures.
  • a wide variety of structurally different modules (i.e. molecules) specific to promote adhesion of certain cells can be synthesized and self-assembled into supermacrocycles and then nanotubular structures according to methods of the present invention.
  • a nanotube is prepared that includes K, RGD and KRSR sidechains.
  • the nanotube can be formed from single base ring structures and twin base ring structures in any desired order.
  • the nanotube can have one or more single base ring structures and one or more twin base ring structures.
  • a nanotube within the scope of the present invention can include a plurality of single base ring structures formed from compounds of Formula I and a plurality of twin base ring structures formed from compounds of Formula II stacked together, i.e. one next to the other via hydrogen bonding, to form the nanotube.
  • implant surfaces are modified to include the nanotubular structures according to the present invention.
  • Implants within the scope of the present invention have particular uses and applications with orthopedics, cartilage, vascular, neural, skin, bladder, cardiovascular, and the like.
  • Implants according to the present invention can be fashioned from one or more materials known to those skilled in the art including metals, ceramics, polymers and copolymers, Specific implant materials include titanium, stainless steel, Co-Cr-Mo, Ti6A14V, nitinol, poly-lactic-co-glycolic acid, poly glycolic acid, poly lactic acid, polyurethane, polycaprolactone, silicone, poly vinyl chloride, alumina, titania, hydroxyapatite, calcium phosphates, zirconia, zinc oxide, silver oxide, and the like.
  • the nanotubular structures are directly applied to the surface of an implant as a coating.
  • the coating can include the nanotubular structures themselves and may further include components known to those skilled in the art to form coatings, such as hydrogels (such as poly-HEMA), hydroxyapatite, calcium phosphates, alumina, titania, polymers (such as poly-lactic, polyurethane, polycaprolactone, silicone, poly vinyl chloride) and the like.
  • the coating may also include cell growth promoting components such as proteins (vitronectin, fibronectin, herparin, etc.) and growth factor/cytokines (TGF- ⁇ , IGF, NGF, VEGF, BMPs, etc.).
  • the coating may also include therapeutically beneficial ingredients such a drugs, hormones, and antibiotics such as penicillin, streptomycin, gentamycin, dexamethasone, estrogen, bisphosphanates, etc. and the like.
  • the coating may be applied to the implant surface using methods known to those of skill in the art such as direct application, dipping, spraying, painting, electrospinning, cast-mold, heat or thermal processes, spin coating and the like. According to one aspect, the coating is dried to retain the coating on the surface prior to application of cells.
  • coatings within the scope of the present invention may be curable onto the surface of an implant using coating compositions and methods known to those of skill in the art.
  • a composition for repair or regeneration of tissue includes one or more nanotubes formed from a plurality of single base ring structures formed from compounds of Formula I. It is to be understood that the compound of formula I need not include a linker or an amino acid or polypeptide and so nanotubes formed from formula I according to the present disclosure need not include a linker or amino acid or a polypeptide. According to an additional embodiment, a composition according to certain aspects can include one or more nanotubes formed from a plurality of twin base ring structures formed from compounds of Formula II.
  • a composition according to certain aspects can include one or more nanotubes formed from a plurality of single base ring structures formed from compounds of Formula I and a plurality of twin base ring structures formed from compounds of Formula II stacked together, i.e. one next to the other via hydrogen bonding, to form the nanotube.
  • the composition includes compounds of formula I or compounds of formula II which can assemble into nanotubes entirely of compounds of formula I or nanotubes entirely of compounds of formula II or nanotubes formed from a mixture of compounds of formula I and formula II.
  • Modules according to the present disclosure can be present in the composition in an amount between about 1 picogram/ml and about 1 kg/ml, about 1 nanogram/ml and about 1 decigram/ml, about 1 microgram/ml and about 1 centigram/ml, about 1 milligram/ml and about 1 gram/ml, about 0.001 mg/ml to about 1 milligram/ml, about 0.005 milligram/ml to about 0.05 milligram/ml and about 0.01 milligram/ml.
  • Nanotubes according to the present disclosure can be present in the composition in an amount between about 1 picogram/ml and about 1 kg/ml, about 1 nanogram/ml and about 1 decigram/ml, about 1 microgram/ml and about 1 centigram/ml, about 1 milligram/ml and about 1 gram/ml, about 0.001 mg/ml to about 1 milligram ml, about 0.005 milligram ml to about 0.05 milligram ml and about 0.01 milligram ml, and all ranges and values in between whether overlapping or not.
  • the composition according to the present disclosure may also include a strengthening compound for providing mechanical strength.
  • the strengthening compound includes phosphates, such as calcium phosphates in the form of granules or powders.
  • Certain calcium phosphates include hydroxyapatite, apatite, oxyapatite, octacalcium phosphate, monocalcium phosphate, dicalcium phosphate, tricalcium phosphate, ⁇ -tricalcium phosphate, a-tricalcium phosphate, tetracalcium phosphate, calcium hydrogen phosphate and calcium dihydrogen phosphate and the like and mixtures thereof including all crystalline and amorphous forms of calcium phosphates.
  • the compound for providing mechanical strength can be present in the composition between about 1 picogram ml and about 1 kg/ml, about 1 nanogram/ml and about 1 decigram/ml, about 1 microgram/ml and about 1 centigram/ml, about 1 milligram/ml and about 1 gram/ml, about 0.001 mg/ml to about 1 milligram/ml, about 0.005 milligram/ml to about 0.05 milligram/ml and about 0.01 milligram/ml, and all ranges and values in between whether overlapping or not.
  • the composition according to the present disclosure may also include a compound for improving the surface roughness. Such surface roughness is present on the surface of an implant or other structure fashioned from the composition.
  • Nanoparticles include compounds having nanometer scale dimensions, such as nanoparticles.
  • Such nanoparticles include calcium phosphate nanoparticles, such as nanoparticles of hydroxyapatite, apatite, oxyapatite, octacalcium phosphate, monocalcium phosphate, dicalcium phosphate, tricalcium phosphate, ⁇ -tricalcium phosphate, a-tricalcium phosphate, tetracalcium phosphate, calcium hydrogen phosphate and calcium dihydrogen phosphate and the like and mixtures thereof including all crystalline and amorphous forms of calcium phosphates.
  • the compound for improving surface roughness can be present in the composition between about 0.0001% to about 99.9999%, about 0.01% to about 75%, about 0.1% to about 50%, about 1% to about 40%, about 2%> to about 30%>, about 5% to about 25%, and about 10%> to about 20%> and all ranges and values in between whether overlapping or not.
  • the diameter size of the nanoparticles can be between about 1 angstrom and about 999 nm, about 10 angstrom and about 500 nm, about 1 nm and about 100 nm, about 10 nm and about 50 nm, and about 20 nm and about 40 nm and all ranges and values in between whether overlapping or not.
  • a compound can provide both properties of both mechanical strength and surface roughness.
  • An exemplary compound providing both mechanical strength and surface roughness are nanoparticles of hydroxyapatite.
  • the amount of hydroxyapatite nanoparticles in the composition can be varied to impart different mechanical strength properties to the implant fashioned from the composition.
  • the composition according to the present disclosure further includes a matrix material. Suitable matrix materials include polymers and hydrogels.
  • the polymers may be nondegradable or nonerodable or resist degradation or erosion.
  • the polymers may be biodegradable or bioerodable.
  • Exemplary polymers include one or more of polylactic acid, polylactide-coglycolide, polyglycolic acid, polymethylmethacrylate, polyurethane, polycaprolactone, polyethylene, polystyrene polypropylene, polypyrrole, poly(2- hydroxyethyl methacrylate) and the like used as matrix materials and combinations thereof.
  • the composition is prepared by combining one or more types of polymerizable components such as monomers of the above polymers, such as hydroxyethyl methacrylate (HEMA) monomers, and/or polymers further capable of polymerizing in combination with nanotubes and the compound for providing mechanical strength and/or surface roughness.
  • HEMA hydroxyethyl methacrylate
  • the polymerizable components are polymerized into a polymer matrix incorporating the nanotubes and the compound for improving mechanical strength and/or surface roughness.
  • Polymerizable components according to the present disclosure can be present in the composition in an amount between about about 0.0001% to about 99.9999%, about 0.01% to about 75%, about 0.1% to about 50%, about 1% to about 40%, about 2% to about 30%, about 5% to about 25%, about 10% to about 20%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, and about 70% to about 90% and all ranges and values in between whether overlapping or not.
  • one embodiment of the composition includes a curable matrix material which cures into a hardened substance.
  • the curable matrix material is cured to form a cured matrix with, for example, nanotubes and nanoparticles of hydroxyapatite embedded therein and present at the surface of the cured matrix.
  • the cured matrix can take any desired shape, such as the shape of a desired mold, for example resembling a tissue defect, such as a bone defect or area of loss of bone or an implant used to reconstruct tissue damage such as a plate or screw.
  • Curable matrix materials include curable resins such as energy curable resins.
  • Curable matrix materials include those that can be cured by exposure to light, such as ultraviolet light, heat, condensation or crosslinking.
  • Curable matrix materials include silicone -based curable materials.
  • compositions can further include components typical for polymerization such as an initiator, a crosslinker, a dispersing agent, a rheology modifier, a filler, and other components useful in producing a polymerizable matrix which can be combined, if desired, with biological components such as proteins, cytokines and growth factors.
  • components typical for polymerization such as an initiator, a crosslinker, a dispersing agent, a rheology modifier, a filler, and other components useful in producing a polymerizable matrix which can be combined, if desired, with biological components such as proteins, cytokines and growth factors.
  • Initiators according to the present disclosure include those known to one of skill in the art, such as azobisisobutyronitrile (AIBN), halogen molecules, azo compounds, organic peroxides and the like, can be present in the composition in an amount between about 0.0001% to about 20%, about 0.001% to about 10%, about 0.01% to about 5%, about 0.1% to about 3%, about 0.1 mg/ml and about 10 mg/ml, about 1 mg/ml and about 5 mg/ml and about 2 mg/ml and about 3 mg/ml and all ranges and values in between whether overlapping or not.
  • AIBN azobisisobutyronitrile
  • Crosslinkers according to the present disclosure include those known to one of skill in the art, such as formalin, formaldehyde, calcium, glutaraldehyde and the like, can be present in the composition in an amount between about 0.0001% to about 99.9999%, about 0.01% to about 75%, about 0.1% to about 50%, about 1% to about 40%, about 2% to about 30%, about 5% to about 25%, about 10% to about 20%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, and about 70% to about 90% and all ranges and values in between whether overlapping or not.
  • compositions can further include excipients, such as saccharide excipients like monosaccharides, disaccharides, water dispersible oligosaccharides and polysaccharides.
  • excipients such as saccharide excipients like monosaccharides, disaccharides, water dispersible oligosaccharides and polysaccharides.
  • compositions can further include binders known to those of skill in the art such as calcium sulfates and calcium silicates.
  • binders include calcium sulfate hemihydrate (CaS0 4 .1/2H 2 0), which reacts with water to form calcium sulfate dihydrate (CaS0 4 .2H 2 0) upon mixing, and tricalcium silicate (CaO)3.Si0 2 (or Ca 3 Si05).
  • an exemplary solidified composition includes pHEMA, about 20% HA, about 3 mg/ml AIBN and about 0.01 mg/ml of a compound of formula II.
  • Exemplary flowable formulations include pHEMA, about 20%-30% water H 2 0, about 2-3 mg/ml AIBN and about 0.01 mg/ml of a compound of formula II.
  • HA may optionally be present in the flowable formulation.
  • cells can be adhered onto the surface of the implants that have been modified with the nanotubular structures of the present invention.
  • Cells within the scope of the present invention include osteoblasts, fibroblasts, endothelial cells, stem cells, keratinocytes, cardiac myocytes, chondrocytes, synoviocytes, mesenchymal stem cells, neural stem cells, islet cells, hepatocytes, smooth muscle cells, urothelial cells, neurons, Schwann cells, etc. and the like.
  • Preferred cells include osteoblasts insofar as the coatings of the present invention convert conventional implant surfaces to biomimetic nanostructured interfaces that enhance cell adhesion and osseointegration.
  • the modules or self-assembled nanotubular structures can be combined with components or suitable medium to produce a composition for an injectable formulation or putty.
  • the composition may also include cell growth promoting components such as proteins (vitronectin, fibronectin, herparin, etc.) and growth factor/cytokines (TGF- ⁇ , IGF, NGF, VEGF, BMPs, etc.).
  • the composition may also include therapeutically beneficial ingredients such a drugs, hormones, antibiotics, such as penicillin, streptomycin, gentamycin, dexamethasone, estrogen, bisphosphanates, etc. and the like.
  • the composition may also include diagnostically beneficial ingredients such a radiolabels, magnetic particles, fluorescent labels, and radio-opaque labels.
  • the bioactive agent when present, may for example be a growth factor such as bone morphogenetic protein (e.g., BMP-1, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15), and one or more different growth factors may be included in the implant.
  • a growth factor such as bone morphogenetic protein (e.g., BMP-1, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15), and one or more different growth factors may be included in the implant.
  • bone morphogenetic protein e.g., BMP-1, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP-10, BMP-11
  • the composition that will form the implant comprises collagen, such as Type I bovine collagen. In other embodiments there is an absence of collagen. Further, in some embodiments, the composition that will form the implant contains one or more non-collagenous fibrous components, such as hydroxybutyrate and/or a cross- linked alginate. These non-collagenous fibrous components may enhance osteoconductivity. In some embodiments the composition contains both crosslinked and non-crosslinked alginates. In other embodiments, the composition contains no alginates, only crosslinked alginates or only non-crosslinked alginates.
  • the composition may include one or more bioactive glasses.
  • a bioactive glass is generally composed of the elements silicon, calcium, phosphorus, sodium, and oxygen, although other elements such as boron, potassium, magnesium and fluorine for example, may be added to modify various characteristics, as disclosed in U.S. Pat. Nos. 4,103,002, 4,775,646 and 4,851,046, the disclosure of which is incorporated herein by reference.
  • a representative bioactive glass composition may comprise for example 40 to 52 wt. % Si0 2 , 10 to 50 wt. % CaO, 10 to 35 wt. % Na 2 0, 2 to 8 wt. % P 2 0 5 , 0 to 25 wt.
  • one specific bioactive glass composition marketed under the brand name BIOGLASS®, has a composition of approximately 21% silicon, 18% calcium, 18% sodium, 3% phosphorus, and 40% oxygen (by weight percent).
  • the compositions that will form the implants contain neither human nor animal tissue derived components. By omitting these types of components, the risk of disease transmission can be reduced, and particularly in embodiments that contain no collagen, the implants will be particularly advantageous for use in applications in which collagen containing products are prohibited.
  • the compositions that will form the implants will also contain a liquid component such as water.
  • the composition that is to be shaped and implanted may be supplied to a provider in a ready to use formulation. For example, a composition that is to be molded to a desired implant shape may be prehydrated and supplied with a syringe or preloaded in a syringe. In some embodiments, hydration is accomplished with sterile water.
  • the implant is designed to be flowable through a syringe as well as to be malleable and cohesive such that it may be intraoperatively shaped and molded to conform to a surgical site. Because these characteristics are present, a health care provider will have a longer time span in which to shape the implant for use in each application. Thus, the composition can be dispensed from the syringe, molded and then inserted by hand into a desired site.
  • the implant may be combined at an operative site with one or more of bone marrow aspirate, autograft tissue, allograft tissue and synthetic grafting agents. It also may be of use in a number of different locations, including but not limited to the spine, orthopedic sites, and COMF.
  • the implant of the present invention is particularly useful for filling of periodontal defects, filling of dental extraction sockets, filling of cystic defects, sinus lifts, alveolar ridge augmentation, oral or maxillofacial augmentation or reconstruction, interbody or posterior-lateral applications, non-loaded bearing defects, and voids caused by trauma. In these and other applications, the implant may be used with or without internal fixation.
  • the components of the composition of the implant are such that there is no setting time.
  • there may be no stabilizers also known as stabilizing agents.
  • the implant may further contain a stabilizing agent, which may be a material that will allow a calcium phosphate mineral to set when reacted after the calcium phosphate has been stored for a predetermined amount of time.
  • this time period is at least one month, at least two months, at least three months, at least four months, at least five months, at least six months. In some embodiments, this time period is less than seven months, less than six months, less than five months, less than four months, less than three months, or less than two months.
  • Examples of the stabilizing agents that can be used in accordance with the present invention include but are not limited to MgO, Mg02, Mg(OH)2, MgHP04, MgHP04.3H20, MgHP04.7H20, Mg3(P04)2, Mg3(P04)2.4H20, Mg3(P04)2.8H20, Mg3(P04)2.22H20, MgC03, MgC03.3H20, MgC03.5H20, 3MgC03Mg(OH)23H20, MgC03Mg(OH)2.3H20, Mg(C3H503)2.3H20, MgC2042H20, Mg(C4H406)2.4H20, MgC03CaC03, Mg2P207, Mg(C12H2302)22H.20, Mg(C14H2702)2, Mg(C18H3302)2, or Mg(C18H3502)2 and/or a mixture thereof.
  • the stabilizing agent is present in an amount of from about 10 ppm to about 60 ppm or from about 30 pm to about 50 ppm or from about 35 ppm to about 45 ppm relative to the total weight of the calcium phosphate.
  • one or more of the following additives is included in addition to the growth factor referenced above or instead of the growth factor referenced above: proteins, X-ray opacifying agents, medicaments, supporting or strengthening filler materials, crystal growth adjusters, viscosity modifiers, pore forming agents and mixtures thereof.
  • the implant may also contain one or more antibiotics.
  • antibiotics include but are not limited to nitroimidazole antibiotics, tetracyclines, penicillins, cephalosporins, carbopenems, aminoglycosides, macrolide antibiotics, lincosamide antibiotics, 4-quinolones, rifamycins and nitrofurantoin.
  • Suitable specific compounds include, without limitation, ampicillin, amoxicillin, benzylpenicillin, phenoxymethylpenicillin, bacampicillin, pivampicillin, carbenicillin, cloxacillin, cyclacillin, dicloxacillin, methicillin, oxacillin, piperacillin, ticarcillin, flucloxacillin, cefuroxime, cefetamet, cefetrame, cefixine, cefoxitin, ceftazidime, ceftizoxime, latamoxef, cefoperazone, ceftriaxone, cefsulodin, cefotaxime, cephalexin, cefaclor, cefadroxil, cefalothin, cefazolin, cefpodoxime, ceftibuten, aztreonam, tigemonam, erythromycin, dirithromycin, roxithromycin, azithromycin, clarithromycin, clindamycin, paldi
  • the antibiotics may be integrated into the composition in the same way that, the growth factor is integrated into it. Further, an antibiotic may be included instead of or in addition to a growth factor.
  • Suitable anti-inflammatory compounds include both steroidal and non-steroidal structures.
  • Suitable non-limiting examples of steroidal anti-inflammatory compounds are corticosteroids such as hydrocortisone, Cortisol, hydroxyltriamcinolone, alpha-methyl dexamethasone, dexamethasone-phosphate, beclomethasone dipropionates, clobetasol valerate, desonide, desoxymethasone, desoxycorticosterone acetate, dexamethasone, dichlorisone, diflorasone diacetate, diflucortolone valerate, fluadrenolone, fluclorolone acetonide, fludrocortisone, flumethasone pivalate, fluosinolone acetonide, fluocinonide, flucortine butylesters, fluocortolone, fluprednidene (fluprednylidene)acetate, flurandrenolone, halcinonide, hydrocortisone acetate, hydrocortisone
  • Non-limiting examples of non-steroidal anti-inflammatory compounds include nabumetone, celecoxib, etodolac, nimesulide, apasone, gold, oxicams, such as piroxicam, isoxicam, meloxicam, tenoxicam, sudoxicam, and CP-14,304; the salicylates, such as aspirin, disalcid, benorylate, trilisate, safapryn, solprin, diflunisal, and fendosal; the acetic acid derivatives, such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin, isoxepac, furofenac, tiopinac, zidometacin, acematacin, fentiazac, zomepirac, clindanac, oxepinac, felbinac, and ketorolac; the fen
  • anti-inflammatories are well-known to those skilled in the art.
  • so-called "natural” anti-inflammatory compounds may be useful. Such compounds may suitably be obtained as an extract by suitable physical and/or chemical isolation from natural sources (e.g., plants, fungi, by-products of microorganisms).
  • natural sources e.g., plants, fungi, by-products of microorganisms.
  • Suitable non-limiting examples of such compounds include candelilla wax, alpha bisabolol, aloe vera, Manjistha (extracted from plants in the genus Rubia, particularly Rubia Cordifolia), and Guggal (extracted from plants in the genus Commiphora, particularly Commiphora Mukul), kola extract, chamomile, sea whip extract, compounds of the Licorice (the plant genus/species Glycyrrhiza glabra) family, including glycyrrhetic acid, glycyrrhizic acid, and derivatives thereof (e.g., salts and esters).
  • Suitable salts of the foregoing compounds include metal and ammonium salts.
  • Suitable esters include C 2 -C 2 4 saturated or unsaturated esters of the acids, preferably Cio-C 2 4, more preferably Ci6-C 2 4.
  • Specific examples of the foregoing include oil soluble licorice extract, the glycyrrhizic and glycyrrhetic acids themselves, monoammonium glycyrrhizinate, monopotassium glycyrrhizinate, dipotassium glycyrrhizinate, 1-beta- glycyrrhetic acid, stearyl glycyrrhetinate, and 3-stearyloxy-glycyrrhetinic acid, and disodium 3-succinyloxy-beta-glycyrrhetinate.
  • pain-reducing agents are included in the definition of pain- reducing agents because they provide pain relief.
  • suitable pain-reducing agents include other types of compounds, such as, for example, opioids (such as, for example, morphine and naloxone), local anaesthetics (such as, for example, lidocaine), glutamate receptor antagonists, a-adrenoreceptor agonists, adenosine, canabinoids, cholinergic and GABA receptors agonists, and different neuropeptides.
  • opioids such as, for example, morphine and naloxone
  • local anaesthetics such as, for example, lidocaine
  • glutamate receptor antagonists such as, a-adrenoreceptor agonists, adenosine, canabinoids, cholinergic and GABA receptors agonists, and different neuropeptides.
  • Compositions of the present disclosure may also include cells.
  • Suitable cells include, without limitations, stem cells, e.g., embryonic or adult stem cells, which can conveniently be derived from the blood or bone marrow of the patient or from an allogeneic source, which preferably is immunologically compatible with the patient.
  • Other suitable cells may include chondrogenic or osteogenic precursor cells.
  • stem cells e.g., embryonic or adult stem cells, which can conveniently be derived from the blood or bone marrow of the patient or from an allogeneic source, which preferably is immunologically compatible with the patient.
  • Other suitable cells may include chondrogenic or osteogenic precursor cells.
  • the cells may be genetically modified (e.g., overexpressing certain proteins, or having expression of certain proteins inhibited). Methods of creating such genetically modified cells are within knowledge and expertise of the person of ordinary skill in the art.
  • compositions of the present disclosure may also include nucleic acid sequences.
  • Suitable nucleic acid sequences include, without limitation, cDNA sequences encoding the at least one bioactive factor of a proteinaceous nature. These cDNAs may be included within respective vectors (e.g., AAV).
  • the nucleic acid sequences may be siR As or shR As or nucleic acid sequences encoding for such siRNAs or shRNAs. These siRNAs and shRNAs may be used in embodiments wherein it is desirable to inhibit expression of certain genes, such as, for example inflammatory protein genes such as TNF, IL-1, IL-6, and BMP inhibitor proteins such Noggin and Chordin, and intracellular BMP inhibitors SMADS.
  • the composition may be soaked in a solution of the at least one bioactive factor before implantation. In some embodiments, depending on the properties of the at least one bioactive factor, the composition may be soaked in the solution for 1- 60 minutes before the implantation.
  • the at least one bioactive factor may also be dripped, brushed, or sprayed onto the composition of the present disclosure or implants including the composition of the present disclosure.
  • the cells may be re-suspended in a volume of media (e.g., Dulbecco's Modified Eagle's Medium) and cultured with the compositions described herein. Due to the properties of the surface of the composition and, in certain instances, the porosity of the composition, the cells will populate the external surfaces of the composition and its internal voids. Optimal loading conditions (e.g., medium composition, shaking, if necessary) may be easily determined by the person of ordinary skill in the art. Further, the composition may be wetted with an aspirate from the patient's bone marrow, thus allowing the bone marrow cells to populate the voids and pores within the composition.
  • media e.g., Dulbecco's Modified Eagle's Medium
  • the carboxyl groups of the protected amino acid Fmoc- Lys(Boc)-OH was first coupled to the hydroxyl groups on the Wang resin.
  • the Fmoc group of the lysine anchored to the resin was removed under basis conditions, after which it was reacted with the second amino acid Fmoc-Arg(PBf)-OH.
  • the same procedure was repeated for subsequent amino acid couplings with Fmoc-Ser(tBu)-OH, Fmoc-Arg(PBf)- OH and Fmoc-y-Abu-OH.
  • the terminal Fmoc group on the Wang resin-supported peptide was removed and the resulting free amine was reductively coupled to CAG aldehyde.
  • the desired motif KRSR-(CAG) 2 was obtained upon deprotection and cleavage from the resin under strongly acidic conditions.
  • the resin was then filtered under vacuum, washed with 10 mL each of CH 2 C1 2 , MeOH, DMF and then treated with 50:50 acetic anhydride/pyridine (5 mL, 1 x 10 min and 2 x 20 min) to cap the unreactive hydroxyl groups.
  • the resin was then filtered and washed with (3 x 10 mL) with DMF, CH 2 C1 2 , and MeOH and dried under vacuum.
  • the substitution degree (0.52 mmol/g) was determined by spectroscopic quantification of the fulvene-piperidine adduct at 301 nm on a resin sample.
  • N- ethyl-N- isopropylpropan-2-amine (DIEA, 8 eq) was added to a mixture of amino acid (4 eq relative to resin loading) and 2-(lH-Benzotriazol-l-yl)-l,l,3,3-tetramethyluronium hexafiuorophosphate (HBTU, 4 eq) in DMF solution, and the mixture was activated by shaking for 3 minutes (min). The resulting mixture was then added to the peptidyl resin and was shaken for 3 hours (h). The peptidyl resin was then drained and washed with 10 mL of each of CH2CI2, MeOH and DMF.
  • DIEA 2-(lH-Benzotriazol-l-yl)-l,l,3,3-tetramethyluronium hexafiuorophosphate
  • the resin was drained and the resulting peptidyl-resin was washed CH2CI2, MeOH and DMF (4 x 10 mL each), and dried under vacuum. Cleavage from the resin and deprotection was achieved by treating the resin with 95% TFA/water for 2 h. The beads were filtered over celite and the resulting filtrate was concentrated to a viscous liquid (rotavap). Cold Et 2 0 was then added to precipitate crude KRSR-(CAG)2, which was isolated by centrifugation. The supernatant liquid was removed by decantation. The residual solid was resuspended in Et 2 0 (2 x 15 mL), sonicated, and centrifuged. The precipitate was dried to yield the desired KRSR-(CAG)2 as an off-white powder.
  • K-RNT m refer to RNTs assembled from functionalized mono base K-CAG.
  • K ⁇ RGD ⁇ RNT 111 and K 95 /RGD 5 -RNT m refer to RNTs co-assembled from mono bases K-CAG and RGD-CAG in a molar ratio of 99 % and 95%, respectively. All the RNT solutions were filtered through a 0.22 ⁇ syringe filter.
  • the grids were then placed onto a droplet of dH 2 0 for 20 s to remove excess non-adherent RNTs before they were placed on a second droplet of 2% aqueous uranyl acetate for 20 s to negatively stain the RNTs.
  • the grids were then dried with filter paper and imaged on a Philips EM410 under an acceleration voltage of 120 kV.
  • the KRSR peptide (not coupled to CAG base) was also imaged as a control experiment.
  • twin bases 0.5 mg/mL were dissolved in dH 2 0 by sonication at room temperature for ⁇ 2 min, The solutions were filtered on 0.25 ⁇ Whatmann filter membrane, heated to boiling (to promote self- assembly), and aged for 1 day. The solutions were diluted to 0.025 mg/mL with dH 2 0 prior to imaging.
  • SEM samples were prepared by floating a carbon-coated 400-mesh copper grid on a droplet of the diluted RNT solution for 10 s. The grid was blotted and floated onto a drop of 2% uranyl acetate for 10 s. The RNT-coated grid was then air- dried and heated on a hot-plate (100°C) for 15 min before imaging on a high resolution Hitachi S-4800 SEM.
  • Titanium (Ti) (1 cm x 1 cm x 0.05 cm) (Alfa Aesar Ti foil) and glass coverslips were soaked in acetone for 15 min, sonicated for 15 min in acetone, and rinsed with dH 2 0. They were then soaked and sonicated in 70% ethanol and rinsed with dH 2 0. Lastly, they were soaked and sonicated in dH 2 0 for another 15 min and rinsed. The glass was then etched in 1 M NaOH for 1 h and thoroughly rinsed in dH 2 0. All of the Ti and glass coverslips were oven-dried overnight and autoclaved for sterilization.
  • the cleaned Ti substrates were coated with the various RNTs (0.01 mg/mL) and KRSR peptide (0.01 mg/mL) solutions for 45 min at room temperature. They were then removed from the solutions and air-dried overnight.
  • a human fetal osteoblast cell line (ATCC, CRL-11372, VA) was cultured in Dulbecco's modified eagle's medium (DMEM, Invitrogen Corporation) supplemented with 10% fetal bovine serum (FBS, Hyclone, UT) and 1% penicillin/streptomycin (P/S, Hyclone, UT) under standard cell culture conditions (37°C, humidified, 5% C0 2 in air). Cells were used up to population numbers of 8-11 in the experiments without further characterization.
  • DMEM Dulbecco's modified eagle's medium
  • FBS fetal bovine serum
  • P/S penicillin/streptomycin
  • a rat skin fibroblast cell line (FR, ATCC, CRL-1213) was cultured in Eagle's Minimum Essential Medium (EMEM, ATCC 30-2003) supplemented with 10% FBS under standard cell culture conditions.
  • Rat aortic endothelial cells (RAEC, VEC Technologies) were cultured in MCDB-131 complete medium (VEC Technologies) under standard cell culture conditions. The fibroblasts were used at population numbers 6-9 and the endothelial cells were used at population numbers 6-11 during culture. The cell medium was replaced every other day.
  • Osteoblasts, fibroblasts and endothelial cells were seeded onto the substrates at a density of 3500 cells/cm 2 and were incubated in the cell culture medium (specifically, DMEM supplemented with FBS and P/S for osteoblasts, EMEM supplemented with FBS for fibroblasts and MCDB-131 complete medium for endothelial cells) for 4 h. Then, the substrates were rinsed three times with a phosphate buffered saline (PBS) to remove nonadherent cells.
  • PBS phosphate buffered saline
  • the remaining cells were fixed using 10% normal buffered formaldehyde (Fisher Scientific) for 10 min and 0.1% Triton X-100 (Sigma-Aldrich, MO) for 5 min. Cells were then stained with rhodamine-phalloidin (staining F-actin filaments, Molecular Probes) to examine cell spreading and were further stained with DAPI (Invitrogen). The cells were observed using a fluorescent microscope (Axiovert 200M, Zeiss) and five different areas of each sample were imaged. The cell density was then determined by counting cells using Image Pro Analyzer. All cellular experiments were run in triplicate and repeated three times for each substrate.
  • KRSR-RNT 1 Compared to uncoated Ti, KRSR-RNT 1 , K 99 /RGD 1 -RNT m , K-RNT m , and AB-RNT 1 did not alter fibroblast adhesion after 4 h ( Figure 7).
  • AB-RNT 1 was assembled from the HC1 and TFA salts of AB-(CAG) 2 . The differences in fibroblast attachment with these two types of RNTs may be associated with their different counter ions.
  • the KRSR peptide did not enhance fibroblast adhesion on Ti.
  • a nanotube incorporating KRSR provides for cell selectivity and utility in orthopedic applications. Finally, many small filopodia extensions from rounded fibroblasts were visible on all substrates, indicating that fibroblasts spread regardless of the Ti coatings ( Figure 8).
  • RNTs Increase Endothelial Cell Adhesion
  • a significantly higher endothelial density on the Ti coated with RNTs was achieved as compared to uncoated Ti after 4 h.
  • AB-RNT 1 (HQ) coated Ti promoted the greatest endothelial cell adhesion compared to all other substrates.
  • KRSR- RNT 1 and KRSR peptide coated Ti did not enhance endothelial cell adhesion.
  • the nanotubes incorporating KRSR selectively promote osteoblast adhesion.
  • Endothelial cell spreading morphologies were shown in Figure 10.
  • Figure 10 shows excellent cytocompatibility properties of K-RNT m and RGD- RNT m for endothelial cell adhesion and the selectivity of KRSR-RNT 1 only for osteoblast adhesion.
  • a thin film of nanostructured RNT coatings with numerous K or RGD side chains alters the surface chemistry and surface roughness of conventional Ti to provide a favorable environment for enhancing endothelial cell adhesion.
  • a nanotube is formed including K or RDG side chains that promote adhesion of endothelial cells and the growth of new blood vessels in bone formed around an orthopedic implant.
  • the nanotube may also include KRSR side chains that promote the adhesion of osteoblasts.
  • a nanotube with a combination of K, RDG and KRSR side chains promotes the selective adhesion of osteoblasts and endothelial cells leading to the formation of new bone tissue useful in orthopedic applications.
  • HA Hydroxyapatite
  • the reaction was carried at 4 °C. First, 30 mL of 0.6 M ammonium phosphate solution was added into 300 ml basic water adjusted by NH 4 OH (pH>10). Then 30 ml of 0.6 M calcium nitrate was added dropwise at 3 ml/min. Following stirring for 10 min, the precipitate was washed three times by centrifugation at 5000 rpm for 5 min. Then, the HA precipitates were treated hydrothermally in a Teflon liner at 200 °C for 20 h. After the hydrothermal step, the precipitate was washed with deionized water once and placed in an oven at 80 °C overnight.
  • Composites of nanotubes, compounds for providing mechanical strength and/or surface roughness and a polymer matrix were prepared as follows.
  • the polymerization process of the composites with varying HA nanoparticle concentrations (2%, 10%, 20%) was initiated by 2,2'-azobisisobutyronitrile (AIBN) via sonication or oven at 60 °C.
  • AIBN 2,2'-azobisisobutyronitrile
  • the mixture of 5 ml HEMA, deionized water and HA nanoparticle powders was sonicated for 20 min, followed by the addition of 0.01 mg/ml TBL molecules of formula II where X is nitrogen, Ri is methyl, R 2 is absent and Y is absent and 3 mg/ml of the AIBN initiator.
  • TBL/HA/pHEMA composites (100% HEMA, 2% HA, 3 mg/ml AIBN, 0.01 mg/ml TBL molecules of formula II where X is nitrogen, Ri is methyl, R 2 is absent and Y is absent) via four heating methods including the oven, water-bath, sonication, or microwave were compared. Then, the temperature profile of the samples (400 ⁇ /tube) using sonication (60 °C, strength 5) and microwave (700 W, 50 s, power 5) were tested using a digital thermometer.
  • the sonication and microwave can reduce the solidification time from more than 40 minutes to several minutes due to the rapid heat-transfer process.
  • Figure 12 shows the results of solidification time as a function of the amount of water (Figure 12a) and AIBN initiator concentration ( Figure 12 b).
  • the solidification time was lengthened with increasing water content or decreasing AIBN initiator concentration.
  • combining low AIBN concentration with high water content resulted in reduced mechanical strength of the composites and increased window time.
  • TBLs of Example 11 were diluted to 0.025 mg/mL in methanol.
  • Clean mica substrates were prepared and the samples were deposited by spin-coating a 0.05-0.25 mg/ml solution on it at 2000 rpm for 20 s. Sample surfaces were observed using a Digital Instruments/V eeco Instruments MultiMode Nanoscope IV AFM equipped with an E scanner. For obtaining optimized height profiles in this investigation, silicon cantilevers (MikroMasch USA, Inc.) with low spring constants of 4.5 N/m were used in tapping mode (TM-AFM). To obtain a clear image from the surface, a low scan rate (0.5- 1 Hz) and amplitude setpoint (I V) were chosen during measurements (Moralez et al 2005).
  • Figure 13 is an atomic force microscopic image of nanotubes formed from twin base linkers of Example 11.
  • sample surfaces (100% HEMA, 3 mg/ml AIBN, 0.01 mg/ml TBLs of Example 11, HA (2%), 10%), 20%o)
  • sample surfaces (100% HEMA, 3 mg/ml AIBN, 0.01 mg/ml TBLs of Example 11, HA (2%), 10%), 20%o)
  • the surface characterization and pore sizes of composites were studied by SEM (LEO 1530-VP) at a scale of 200 nm and 100 ⁇ .
  • the composites exhibit porosity which promote the growth of tissue into and through the implanted composites.
  • Pore sizes can be between about 1 angstrom and about 999 microns in diameter.
  • Pore density can be between about 0.0001% and about 99.9999%.
  • a human fetal osteoblast cell line (ATCC, CRL-11372, VA) was cultured in Dulbecco's modified eagle's medium (DMEM, Invitrogen Corporation) supplemented with 10% fetal bovine serum (FBS, Hyclone, UT) and 1% penicillin/streptomycin (P/S, Hyclone, UT) under standard cell culture conditions (37°C, humidified, 5% C0 2 /95%> air). Cells were used up to population numbers of 3 in experiments without further characterization.
  • DMEM Dulbecco's modified eagle's medium
  • FBS fetal bovine serum
  • P/S penicillin/streptomycin
  • a rat skin fibroblast cell line (FR, ATCC, CRL-1213) was cultured in Eagle's Minimum Essential Medium (EMEM, ATCC, 30-2003) supplemented with 10% FBS under standard cell culture conditions.
  • EMEM Eagle's Minimum Essential Medium
  • Rat aortic endothelial cells (RAEC, VEC Technologies) were cultured in MCDB-131 complete medium (VEC Technologies) under standard cell culture conditions.
  • the fibroblasts were used at population numbers 6-9. Fibroblast and endothelial cell toxicity was not affected at the concentrations used which demonstrated that the compositions were not toxic at various concentrations.
  • Osteoblasts and fibroblasts were separately seeded onto the substrates at a density of 3500 cells/cm 2 and were incubated in the cell culture medium (specifically, DMEM supplemented with FBS and P/S for osteoblasts and EMEM supplemented with FBS for fibroblasts) for 4 h. Then, the substrates formulated above were rinsed three times with a phosphate buffered saline (PBS) to remove non-adherent cells. The remaining cells were fixed using 10% normal buffered formaldehyde (Fisher Scientific) for 10 min and 0.1% Triton X-100 (Sigma- Aldrich, MO) for 5 min.
  • PBS phosphate buffered saline
  • Cells were then stained with rhodamine- phalloidin (staining F-actin filaments, Molecular Probes) to examine cell spreading and further stained with DAPI (Invitrogen). The cells were observed using a fluorescence microscope (Axiovert 200M, Zeiss) and five different areas of each sample were imaged. The cell density was determined by counting cells using Image Pro Analyzer. All cellular experiments were run in triplicate and repeated three times for each substrate.
  • rhodamine- phalloidin staining F-actin filaments, Molecular Probes
  • DAPI Invitrogen
  • Figure 20 demonstrates increased osteoblast density and decreased fibroblast density with increasing hydroxyapatite in combination with nanotubes formed from twin base linker modules of Example 11.
  • Osteoblasts were prepared as described above, seeded randomly onto the substrate surface, and cultured under standard cell culture conditions for longer (1, 3, and 5 days) time periods. Osteoblast proliferation was assessed by measuring the amount of DNA in papin-digests using Hoeschst 33258 dye (Sigma) and a fluorospectrophotometer (Milton Roy Company, Fluorospectronic). The number of cells in the experimental samples was determined from a standard curve correlating the amount of DNA per known number of cells (assay sensitive to approximately 1,000). Proliferation at these long-time periods was reported as cell density (cells per unit surface area).
  • Figure 21 demonstrates increased osteoblast proliferation with increasing hydroxyapatite content in combination with nanotubes formed from twin base linker modules of Example 11.
  • Osteoblasts were prepared as described above, seeded randomly onto the substrate surface, and cultured under standard cell culture conditions for longer (1, 3, and 5 days) time periods. Osteoblast proliferation was assessed by measuring the amount of DNA in papin-digests using Hoeschst 33258 dye (Sigma) and a fluorospectrophotometer (Milton Roy Company, Fluorospectronic). The number of cells in the experimental samples was determined from a standard curve correlating the amount of DNA per known number of cells (assay sensitive to approximately 1,000). Proliferation at these long-time periods was reported as cell density (cells per unit surface area).
  • the substrates were first rinsed with Tris-buffered saline (TBS; a solution consisting of 42 mM Tris-HCl, 8 mM Tris Base and 0.15 M NaCl adjusted to a pH of 7.4; all chemicals from Sigma) three times and then the osteoblasts were lysed using distilled water and three freeze-thaw cycles.
  • TBS Tris-buffered saline
  • Total protein content in the cell lysates was determined spectrophotometrically using a BCA Protein Assay Reagent Kit (Pierce Chemical Co.) following manufacturer's instructions.
  • each sample lysate was incubated with 200 ⁇ of the working reagent (containing cupric sulfate and bicinchoninic acid) at 37 °C for 30 min. Then, the light absorbance of these samples was measured by a spectrophotometer (SpectroMAX; Molecular Devices) at 562 nm.
  • SpectroMAX SpectroMAX; Molecular Devices
  • Total intracellular protein synthesized by osteoblasts cultured on the substrates was determined from a standard curve of absorbance versus known concentrations of albumin run in parallel with experimental samples. The total intracellular protein synthesis was normalized by substrate surface area.
  • Collagen is a well-known protein contained in the extracellular matrix of bone. To determine these amounts, cell lysates were prepared as described above. 50 ⁇ of osteoblast lysates were added per well of a 96-well plate (Corning). The collagen was allowed to dry on the plate through incubation at 37 °C for 16 hours and was then incubated at 37 °C for 24 hours in the presence of a desiccant (W.A. Hamond Drierite Company LTD.). Thereafter, the 96-well plate was rinsed three times with distilled water (1 min per wash and 200 ⁇ per well).
  • Figure 22 demonstrates increased osteoblast collagen synthesis by osteoblasts with increasing hydroxyapatite content in combination with nanotubes formed from twin base linker modules of Example 11.
  • Alkaline phosphatase activity Alkaline phosphatase is an enzyme whose synthesis indicates the differentiation of osteoblasts from non-calcium depositing to calcium depositing cells.
  • cell lysates were prepared as previously described and a commercial Alkaline/Acid Phosphatase Assay Kit (Upstate) was used to determine the concentration of alkaline phosphatase in these cell lysates following manufacturer's instructions. Aliquots of the distilled water supematants were first mixed and incubated with 40 mM NiCl 2 , 5 mg/ml BSA, 1 mM phosphopeptide solution, and Pnpp Ser/Thr Assay Buffer at 37 °C for 10-15 min.
  • FIG. 23 demonstrates increased alkaline phosphatase synthesis by osteoblasts with increasing hydroxyapatite content in combination with nanotubes formed from twin base linker modules of Example 11.
  • Figure 24 demonstrates increased osteoblast calcium deposition by osteoblasts with increasing hydroxyapatite content in combination with nanotubes formed from twin base linker modules of Example 11.
  • nanometer scale structures that are formed from modules that preferably self-assemble into substructures, which themselves self-assemble into nanometer scale architectures or structures, when placed in an aqueous environment (e.g., water, body fluids, etc.).
  • Modules according to the present invention include compounds of Formula I as set forth herein.
  • Modules according to the present invention also include compounds of Formula II as set forth herein.
  • the novel modules of the present invention, and the novel structures formed therefrom will sometimes hereinafter be referred to as simply "the novel composition”.
  • various components may be included in the novel composition so as to provide the novel composition with desired characteristics, e.g., structural integrity, strength, surface roughness, curing attributes, flowability, bioactivity (e.g., to promote tissue growth), anti-inflammatory attributes, nucleic acid sequences, etc.
  • desired characteristics e.g., structural integrity, strength, surface roughness, curing attributes, flowability, bioactivity (e.g., to promote tissue growth), anti-inflammatory attributes, nucleic acid sequences, etc.
  • water is used as a catalyst to cause the aforementioned modules to assemble into different structures.
  • the quantity of water may be adjusted so as to vary the length of the nanotube structures which are produced.
  • the use of less water may promote the production of shorter nanotubes, which can be useful in creating compounds for disposition of the adjacent bone, whereby to promote the growth of new bone.
  • the use of more water may promote the production of longer nanotubes, which can be useful in creating compounds for disposition adjacent cartilage, whereby to promote the growth of new cartilage.
  • hydroxyapatite "HA" can be included in the novel composition in order to modify the characteristics of the novel composition.
  • HA can be included in the novel composition so that the novel composition will "mimic” bone, whereby to promote the growth of new bone,
  • HA can be excluded from the novel composition so that the novel composition will mimic cartilage, whereby to promote the growth of new cartilage.
  • tissue- promoting structures include hydrogels such as poly (2-hydroxyethyl methacrylate) (“poly-HEMA”, or simply “pHEMA”) and azobisisobutyronitrile (“AIBN”).
  • poly-HEMA poly (2-hydroxyethyl methacrylate
  • AIBN azobisisobutyronitrile
  • ⁇ represents an increase in the property when the component is increased
  • V represents a decrease in the property when the component is increased
  • - represents no change in the property when the component is increased
  • TBL indicates a compound of Formula II referred to herein as a twin base linker, although compounds of Formula I may also be used.
  • compositions disclosed herein may be used with implants, coatings for medical devices, and topical products for topical use.
  • specific formulation of the novel compound, and the processing steps used to produce the same may be adjusted according to the application intended.
  • implants may be produced for, among other things, orthopedic/periodontal applications and wound-healing applications.
  • the orthopedic/periodontal applications include the production of implants using novel compositions engineered to promote bone growth and tissue growth, such as soft tissue growth.
  • the bone growth compositions may be used to produce prefabricated implants and injectable implants (e.g., to be cured in situ).
  • pre-fabricated implants may include total joint implants, solid articular cartilage implants, dental implants, etc.
  • injectable implants may include meniscal cartilage implants for curing in situ.
  • An exemplary formulation for an injectable implant includes a mix of 100% pHEMA, 20% HA, 20-30% H 2 0, 2-3 mg/ml AIBN and 0.01 mg/ml TBL.
  • An exemplary formulation for a pre-fabricated implant includes a mix of 100% pHEMA, 20% HA, 3 mg/ml AIBN and 0.01 mg/ml TBL.
  • the exemplary formulation for a pre-fabricated implant can be processed using a step of heating using an oven, water bath, sonication, microwave or other suitable method or device to heat the formulation.
  • the formulation is heated to 60°C, at strength 5 for 5 minutes.
  • the formulation may be heated in a mold at 60°C for 40 minutes.
  • soft tissue implants may include ligaments, etc.
  • An exemplary formulation for such a soft tissue implant includes a mix of 100% pHEMA, 20-30% H 2 0, 2-3 mg/ml AIBN and 0.01 mg/ml TBL.
  • the wound-healing implants may be engineered for, among other things, skin regeneration.
  • An exemplary formulation for such a wound healing implant includes a mix of TBLs, H 2 0, initiator, and carrier(s).
  • coatings including TBL formulations may be provided for orthopedic/periodontal applications and antimicrobial applications.
  • such coatings may be provided for total joints or dental implants and may increase tissue-implant cohesion.
  • antimicrobials including TBLs may be provided for infection control and may be used on catheters, wound dressings, etc.
  • topical products including TBLs may be used for dermatology/skin care applications.
  • An exemplary formulation for a dermatology/skin care product includes TBLs, H 2 0, initiator and carrier(s).
  • HEMA 2-hydroxyethyl methacrylate
  • TBL dH 2 0, TBL (0.01 mg/mL)
  • AIBN initiator 2,2'-azobisisobutyronitrile
  • TBL/pHEMA composites were sterilized by soaking in 70% ethanol for 20 min and exposed to ultraviolet (UV) light overnight before cell experiments.
  • UV ultraviolet
  • the TBL/HA/pHEMA composite solution was placed into dog-bone shaped molds (3.18 mm in width, 4 mm in thickness and 7.62 mm in gage length) and then into an oven (60°C, 2 h).
  • the Instron 5882 mechanical testing system was used to determine the tensile properties of samples at a speed of 5 mm/min under dry conditions.
  • Cell adhesion and proliferation studies To determine the adhesion density and proliferation viability of chondrocytes and fibroblast, the cell proliferation assay (CellTiter 96, Promega) was used. Briefly, cells were seeded at 3,500 cells/cm 2 in standard cell culture media and incubated for 4 hours, 1 day, and 3 days. The dye solution was added to the cells after the end of the prescribed period for 4 h, then the stop solution was added and incubated overnight. A plate reader was used to test the cell density.
  • Total protein synthesis Total protein content in the cell lysates was measured using a commercial BCATM Protein Assay Reagent Kit (Pierce Biotechnology) and following the manufacturer's instructions. Aliquots from the supernatants of the protein-containing cell lysates (150 ⁇ ) were mixed with the reagent solutions and incubated at 37°C for 2 h. Optical absorbance was measured at 562 nm on a spectrophotometer (SpectraMax 340PC, Molecular Devices).
  • GAG synthesis For chondrocyte differentiation studies, chondrocytes were seeded at a seeding density of 10,000 cells/cm 2 onto the substrates. Cells were cultured for 3 and 5 days under standard cell culture conditions with chondrogenic medium. Glycosaminoglycan (GAG) concentration was measured spectrophotometrically by a 1- 9- dimethylmethylene blue (DMMB) dye assay.
  • GAG Glycosaminoglycan
  • composites containing nanotubes of the TBLs had higher chondrocyte cell density than composite without nanotubes of the TBLs.
  • the formulation with 20% H 2 0 that formed the composite had the highest cell density.
  • water is retained within the composite.
  • the amount of water in the formulation that forms the composite is related to the amount of water that is retained in the composite.
  • the higher the amount of water in the composite the more flexible the composite is, or stated differently, the less stiff is the composite.
  • lessening the stiffness of the composite may increase adhesion, growth or proliferation of cells to the composite.
  • the bone augmentation was performed by excising a 4 mm diameter and 4 mm long bone femur segment.
  • the bone graft material including nanotubes of the TBL was then directly inserted.
  • animals were sacrificed and new bone growth was assessed by histological analysis. Specifically, histology included Masson-Goldner stains. New bone and tissue growth was assessed using histomorphometric analysis.
  • FIG. 32 the average area of tissue ingrowth at 4 weeks for rabbits implanted with the composite of TBL and 20% hydroxyapatite far exceeded a control.
  • Figure 33 the average tissue ingrowth distance at 4 weeks for rabbits implanted with the composite of TBL and 20% hydroxyapatite far exceeded a control.
  • Figure 34 is a histology of tissue comparing bone growth after 4 weeks for a control and an implant composite of TBL and 20% hydroxyapatite.
  • FIG 35 the average area of tissue ingrowth at 8 weeks for rabbits implanted with the composite of TBL and 20% hydroxyapatite far exceeded a control.
  • Figure 36 the average tissue ingrowth distance at 8 weeks for rabbits implanted with the composite of TBL and 20% hydroxyapatite far exceeded a control.
  • Figure 37 is a histology of tissue comparing bone growth after 8 weeks for a control and an implant composite of TBL and 20% hydroxyapatite.
  • Figure 38 is a histology of tissue comparing bone growth after 12 weeks for a control and an implant composite of TBL and 20% hydroxyapatite.

Abstract

Des modes de réalisation de la présente invention concernent des procédés consistant à modifier la surface d'un substrat afin d'améliorer l'adhésion, la prolifération et/ou la différenciation cellulaire sur la surface du substrat. Les substrats dans la portée de la présente invention comprennent des surfaces d'implant où l'adhésion cellulaire est souhaitée et/ou la croissance cellulaire et/ou la différenciation cellulaire sur le substrat lui-même ou à l'emplacement de l'implant dans le corps.
PCT/US2012/056674 2011-09-21 2012-09-21 Nanotubes et compositions de ceux-ci WO2013044105A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161537389P 2011-09-21 2011-09-21
US61/537,389 2011-09-21

Publications (1)

Publication Number Publication Date
WO2013044105A1 true WO2013044105A1 (fr) 2013-03-28

Family

ID=47914917

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/056674 WO2013044105A1 (fr) 2011-09-21 2012-09-21 Nanotubes et compositions de ceux-ci

Country Status (1)

Country Link
WO (1) WO2013044105A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113274412A (zh) * 2021-04-28 2021-08-20 山东大学 通用型钙制剂在神经干细胞分化调节上的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050131230A1 (en) * 2001-01-17 2005-06-16 Hicham Fenniri Method and associated compounds for forming nanotubes
WO2009009666A2 (fr) * 2007-07-12 2009-01-15 Nanovis, Inc Procédé permettant d'accroître la fonction ostéoblastique et de mesurer les propriétés électrochimiques d'un implant médical
US20110085968A1 (en) * 2009-10-13 2011-04-14 The Regents Of The University Of California Articles comprising nano-materials for geometry-guided stem cell differentiation and enhanced bone growth
WO2011116085A1 (fr) * 2010-03-16 2011-09-22 Brown University Nanotubes et compositions associées

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050131230A1 (en) * 2001-01-17 2005-06-16 Hicham Fenniri Method and associated compounds for forming nanotubes
WO2009009666A2 (fr) * 2007-07-12 2009-01-15 Nanovis, Inc Procédé permettant d'accroître la fonction ostéoblastique et de mesurer les propriétés électrochimiques d'un implant médical
US20110085968A1 (en) * 2009-10-13 2011-04-14 The Regents Of The University Of California Articles comprising nano-materials for geometry-guided stem cell differentiation and enhanced bone growth
WO2011116085A1 (fr) * 2010-03-16 2011-09-22 Brown University Nanotubes et compositions associées

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHANG ET AL.: "Nanotechnology and Nanomaterials: Promises for Improved Tissue Regeneration.", NANO TODAY, vol. 4, 2009, pages 66 - 80, XP025659163 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113274412A (zh) * 2021-04-28 2021-08-20 山东大学 通用型钙制剂在神经干细胞分化调节上的应用

Similar Documents

Publication Publication Date Title
US10201634B2 (en) Nanotubes and compositions thereof
Xin et al. Programmed sustained release of recombinant human bone morphogenetic protein-2 and inorganic ion composite hydrogel as artificial periosteum
Wu et al. Biomimetic porous scaffolds for bone tissue engineering
Behzadi et al. Nanomedicine for safe healing of bone trauma: opportunities and challenges
Hu et al. Regulation of the differentiation of mesenchymal stem cells in vitro and osteogenesis in vivo by microenvironmental modification of titanium alloy surfaces
Singh et al. Mesoporous silica-layered biopolymer hybrid nanofibrous scaffold: a novel nanobiomatrix platform for therapeutics delivery and bone regeneration
Wu et al. Biomimetic mineralization of novel hydroxyethyl cellulose/soy protein isolate scaffolds promote bone regeneration in vitro and in vivo
Schuler et al. Biomedical interfaces: titanium surface technology for implants and cell carriers
He et al. Collagen‐infiltrated porous hydroxyapatite coating and its osteogenic properties: In vitro and in vivo study
Bosco et al. Instructive coatings for biological guidance of bone implants
Paul et al. Nanoceramic matrices: biomedical applications
EP2678048B1 (fr) Technologie de nano-réservoirs utilisée pour une régénération osseuse et/ou cartilagineuse
Schliephake Application of bone growth factors—the potential of different carrier systems
Griffanti et al. Bioinspired mineralization of a functionalized injectable dense collagen hydrogel through silk sericin incorporation
Wu et al. Growth factors enhanced angiogenesis and osteogenesis on polydopamine coated titanium surface for bone regeneration
Gümüşderelioğlu et al. Chitosan-based double-faced barrier membrane coated with functional nanostructures and loaded with BMP-6
Yao et al. Three-dimensional coating of SF/PLGA coaxial nanofiber membranes on surfaces of calcium phosphate cement for enhanced bone regeneration
Yun et al. The effect of bone morphogenic protein-2 (BMP-2)-immobilizing heparinized-chitosan scaffolds for enhanced osteoblast activity
Du et al. Surface polydopamine modification of bone defect repair materials: Characteristics and applications
Wei et al. Aptamer/hydroxyapatite-functionalized titanium substrate promotes implant osseointegration via recruiting mesenchymal stem cells
Fardjahromi et al. Enhancing osteoregenerative potential of biphasic calcium phosphates by using bioinspired ZIF8 coating
Bishal et al. Enhanced bioactivity of collagen fiber functionalized with room temperature atomic layer deposited titania
Poddar et al. Influence of varying concentrations of chitosan coating on the pore wall of polycaprolactone based porous scaffolds for tissue engineering application
Chen et al. Biofunctional coatings for dental implants
Cai et al. Bioinspired fabrication of calcium-doped TiP coating with nanofibrous microstructure to accelerate osseointegration

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12834221

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12834221

Country of ref document: EP

Kind code of ref document: A1